ETNB News and Press, 89bio Inc. From 06/16/21

SAN FRANCISCO, June 16, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company’s Ma...

89bio (ETNB) has initiated ENLIVEN, a Phase 2b trial evaluating BIO89-100 for the treatment of patients with fibrosis stage 2 or 3 non-alcoholic steatohepatitis ((NASH)).A total of 216 patients will receive either one of two weekly doses (15mg or 30mg) or an every two-week dose (44mg) of BIO8...

SAN FRANCISCO, June 10, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the initiation of ENLIVE...

Canopy set for growth on Canadian economy re-openingWhile not expecting a significant Q4 2021 beat for Canopy Growth (CGC) on June 1, MKM expects a turnaround as the Canadian economy starts to re-open.As a result, the firm is upgrading shares from neutral to buy with a C$55 price target.That ...

Gainers: Scopus BioPharma SCPS +164%, Aptorum APM +32%, Obalon Therapeutics (OBLN) +25%, Taiwan Liposome TLC +18%, Strongbridge Biopharma SBBP +14%.Losers: NGM Biopharmaceuticals NGM -37%, Onconova Therapeutics (ONTX) -14%, ...

89bio (ETNB): Q1 GAAP EPS of -$0.74 misses by $0.04.As of March 31, 2021, 89bio had cash, cash equivalents, and short-term investments of $189.6 million.Press Release For further details see: 89bio EPS misses by $0.04

SAN FRANCISCO, May 12, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today reported its financial results for ...

89bio ([[ETNB]] +6.9%) has surged today after Cantor Fitzgerald initiated coverage on the stock with an overweight rating and the price target at $58.00 per share implies as much as ~124.7% premium to the previous close.89bio’s lone asset BIO89-100 is set to undergo a Phase 2b tri...

An update on the 20 life sciences companies Numenor Capital has profiled so far range from cell therapy companies like SQZ Biotech and Orchard Therapeutics to biologics platforms like Pandion. The best performing investment, over 170% return, so far has been Pandion Therapeutics that ...

- Received written guidance from FDA related to trial design and agreement to use liquid formulation - - ENLIVEN trial to initiate as planned in 2Q21 - SAN FRANCISCO, April 05, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focu...